Roundhill Cannabis ETF (BATS: WEED) Momentum Soars to 89.25 Amid Federal Reform Optimism
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Should l Buy ACB?
Source: Benzinga
- Surging Momentum: The Roundhill Cannabis ETF's momentum score has surged to 89.25, placing it in the 89th percentile among industry peers, significantly outperforming Aurora Cannabis's score of 21.25, indicating strong investor confidence amid federal cannabis reform optimism.
- Short-Term Strength: While the ETF has shown a robust short-term performance with a 61.50% increase over the last six months, the medium-term trend remains negative, suggesting that investors should prepare for volatility and a multi-stage adjustment process.
- Policy Catalyst: President Trump's push to reschedule cannabis to Schedule 3 is viewed as the most significant federal policy shift in 50 years, which could eliminate the burdensome Section 280E tax, greatly enhancing the profitability of U.S. operators.
- 2026 Performance Decline: Despite the strong momentum, the Roundhill ETF has declined by 4.72% in 2026 so far, closing at $19.38 on Tuesday, reflecting short-term market uncertainty and volatility.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACB
Wall Street analysts forecast ACB stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.200
Low
6.28
Averages
6.77
High
7.39
Current: 3.200
Low
6.28
Averages
6.77
High
7.39
About ACB
Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company’s principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally. The Company’s segments include Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, IndiMed and CraftPlant. The Company also holds a 50.1% controlling interest in Bevo Farms Ltd., a supplier of propagated vegetables and ornamental plants in North America. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aurora Named on Women Lead Here List for Second Year
- Recognition of Leadership: Aurora Cannabis has been named on The Globe and Mail's 2026 Women Lead Here list for the second consecutive year, highlighting the company's ongoing commitment to gender diversity at the executive level, with 50% female executives enhancing its image and ability to attract female talent.
- Cultural Development: Lori Schick, Executive VP of Human Resources at Aurora, stated that the company fosters a culture of respect, trust, and accountability, enabling female leaders to thrive and drive business forward, thereby improving overall performance and market competitiveness.
- Industry Impact: The benchmark evaluates executive teams at Canada's largest publicly traded companies using a data-driven methodology that emphasizes sustainable representation, with Aurora standing out among 85 companies, showcasing its leadership position and commitment to diversity in the industry.
- Strategic Direction: Aurora remains focused on creating an environment that encourages collaboration and diverse perspectives, which not only enhances service quality for patients and communities but also lays a solid foundation for the company's future growth.
See More
Aurora Cannabis Recognized on Women Lead Here List for Second Year
- Diversity Recognition: Aurora Cannabis has been named on The Globe and Mail's 2026 Women Lead Here list for the second consecutive year, reflecting the company's ongoing commitment to gender diversity at the executive level, with a 50% female leadership ratio that enhances its image and ability to attract female talent.
- Cultural Development: Lori Schick, Executive Vice President of Human Resources, emphasizes that Aurora fosters a culture grounded in respect, trust, and accountability, enabling female leaders to thrive and drive the company forward, which boosts employee satisfaction and teamwork.
- Industry Influence: The benchmark evaluates executive teams of Canada's largest publicly traded companies using a data-driven methodology that prioritizes measurable progress and sustained representation, with Aurora's inclusion not only enhancing its reputation in the industry but also setting a standard for others.
- Global Market Expansion: As a global leader in medical cannabis, Aurora is dedicated to improving patient lives through scientific expertise and high-quality products, continuously expanding its presence in Canada, Europe, Australia, and New Zealand, thereby solidifying its leadership position in the medical cannabis sector.
See More
Aurora Cannabis Faces Significant Challenges Ahead
- Poor Market Performance: Aurora Cannabis has lost 96% of its stock value since 2021, indicating the company's struggle to establish itself in a highly competitive market; despite cannabis being legalized in Canada since 2018, Aurora has failed to achieve significant success, highlighting deficiencies in its market strategy.
- Regulatory Change Opportunities: President Trump’s executive order reclassifying cannabis to Schedule III offers research and banking advantages, yet Aurora's negligible presence in the U.S. market limits its potential gains from these changes, constraining growth opportunities.
- Acquisition Challenges: The acquisition of Reliva, focused on CBD products, in 2020 was undermined by significant challenges in the CBD market, leading to the shutdown of operations in 2023, which underscores the difficulties and risks Aurora faces in expanding into new markets.
- Bleak Future Outlook: While a potential cannabis market revival exists, Aurora Cannabis's weak revenue growth and consistent net losses present substantial challenges for re-entering the U.S. market, prompting investors to carefully assess the company's future performance amidst these uncertainties.
See More
Aurora Cannabis Faces Significant Challenges Amid Regulatory Changes
- Stock Price Plunge: Aurora Cannabis has seen its shares plummet by 96% since 2021, indicating severe financial distress and a significant loss of investor confidence in its future prospects amid fierce market competition.
- Limited Market Opportunities: Despite recent regulatory changes in the U.S. that could create new cannabis market opportunities, Aurora Cannabis has virtually no presence in the U.S. market and shut down its Reliva operations in 2023, highlighting challenges in the CBD sector.
- Financing Challenges: Should Aurora Cannabis seek to re-enter the U.S. market, it may need to pursue dilutive financing methods for acquisitions, further eroding existing shareholder value and increasing investment risks.
- Investor Confidence Lacking: Given Aurora Cannabis's weak revenue growth and consistent net losses, analysts generally view the company as a poor choice to capitalize on any upcoming cannabis market boom, potentially positioning it as a wealth destroyer.
See More
Aurora Cannabis to Discuss Growth Strategy at TD Cowen Conference
- Conference Participation: Aurora Cannabis CFO Simona King will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026, where she is expected to engage in one-on-one meetings with investors, showcasing the company's leadership in the global medical cannabis market.
- Market Trends Discussion: The conference will explore significant shifts in the global medical cannabis landscape and their impact on industry growth, with Aurora sharing insights on its excellence in Canadian manufacturing, further solidifying its market position.
- Completion of Bevo Transaction: Aurora announced the completion of its transaction with Bevo Agtech Inc., initially announced on February 4, 2026, marking a significant step in expanding its product lines and market share.
- Global Expansion Strategy: As a global leader in medical cannabis, Aurora is committed to improving patient lives through scientific expertise and high-quality products, and will continue to expand its operations in markets such as Canada, Europe, and Australia.
See More
Aurora Cannabis to Discuss Growth Strategy at Health Care Conference
- Conference Participation: Aurora Cannabis will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026, where CFO Simona King will engage in discussions, likely drawing investor attention to its international leadership and market opportunities.
- Market Trends Discussion: The conference will address significant shifts in the global medical cannabis industry and market forces, with Aurora aiming to reinforce its market leadership by showcasing its excellence in Canadian manufacturing.
- Completion of Bevo Transaction: Aurora announced the completion of its transaction with Bevo Agtech Inc., previously disclosed on February 4, 2026, marking a strategic advancement in expanding its product lines and market share.
- Global Expansion Strategy: As a global leader in medical cannabis, Aurora is committed to improving patient lives through scientific expertise and high-quality products, and will continue to seek high-margin opportunities in Canada, Europe, and other markets.
See More
Aurora Named on Women Lead Here List for Second Year
- Recognition of Leadership: Aurora Cannabis has been named on The Globe and Mail's 2026 Women Lead Here list for the second consecutive year, highlighting the company's ongoing commitment to gender diversity at the executive level, with 50% female executives enhancing its image and ability to attract female talent.
- Cultural Development: Lori Schick, Executive VP of Human Resources at Aurora, stated that the company fosters a culture of respect, trust, and accountability, enabling female leaders to thrive and drive business forward, thereby improving overall performance and market competitiveness.
- Industry Impact: The benchmark evaluates executive teams at Canada's largest publicly traded companies using a data-driven methodology that emphasizes sustainable representation, with Aurora standing out among 85 companies, showcasing its leadership position and commitment to diversity in the industry.
- Strategic Direction: Aurora remains focused on creating an environment that encourages collaboration and diverse perspectives, which not only enhances service quality for patients and communities but also lays a solid foundation for the company's future growth.
See More
Aurora Cannabis Recognized on Women Lead Here List for Second Year
- Diversity Recognition: Aurora Cannabis has been named on The Globe and Mail's 2026 Women Lead Here list for the second consecutive year, reflecting the company's ongoing commitment to gender diversity at the executive level, with a 50% female leadership ratio that enhances its image and ability to attract female talent.
- Cultural Development: Lori Schick, Executive Vice President of Human Resources, emphasizes that Aurora fosters a culture grounded in respect, trust, and accountability, enabling female leaders to thrive and drive the company forward, which boosts employee satisfaction and teamwork.
- Industry Influence: The benchmark evaluates executive teams of Canada's largest publicly traded companies using a data-driven methodology that prioritizes measurable progress and sustained representation, with Aurora's inclusion not only enhancing its reputation in the industry but also setting a standard for others.
- Global Market Expansion: As a global leader in medical cannabis, Aurora is dedicated to improving patient lives through scientific expertise and high-quality products, continuously expanding its presence in Canada, Europe, Australia, and New Zealand, thereby solidifying its leadership position in the medical cannabis sector.
See More
Aurora Cannabis Faces Significant Challenges Ahead
- Poor Market Performance: Aurora Cannabis has lost 96% of its stock value since 2021, indicating the company's struggle to establish itself in a highly competitive market; despite cannabis being legalized in Canada since 2018, Aurora has failed to achieve significant success, highlighting deficiencies in its market strategy.
- Regulatory Change Opportunities: President Trump’s executive order reclassifying cannabis to Schedule III offers research and banking advantages, yet Aurora's negligible presence in the U.S. market limits its potential gains from these changes, constraining growth opportunities.
- Acquisition Challenges: The acquisition of Reliva, focused on CBD products, in 2020 was undermined by significant challenges in the CBD market, leading to the shutdown of operations in 2023, which underscores the difficulties and risks Aurora faces in expanding into new markets.
- Bleak Future Outlook: While a potential cannabis market revival exists, Aurora Cannabis's weak revenue growth and consistent net losses present substantial challenges for re-entering the U.S. market, prompting investors to carefully assess the company's future performance amidst these uncertainties.
See More
Aurora Cannabis Faces Significant Challenges Amid Regulatory Changes
- Stock Price Plunge: Aurora Cannabis has seen its shares plummet by 96% since 2021, indicating severe financial distress and a significant loss of investor confidence in its future prospects amid fierce market competition.
- Limited Market Opportunities: Despite recent regulatory changes in the U.S. that could create new cannabis market opportunities, Aurora Cannabis has virtually no presence in the U.S. market and shut down its Reliva operations in 2023, highlighting challenges in the CBD sector.
- Financing Challenges: Should Aurora Cannabis seek to re-enter the U.S. market, it may need to pursue dilutive financing methods for acquisitions, further eroding existing shareholder value and increasing investment risks.
- Investor Confidence Lacking: Given Aurora Cannabis's weak revenue growth and consistent net losses, analysts generally view the company as a poor choice to capitalize on any upcoming cannabis market boom, potentially positioning it as a wealth destroyer.
See More
Aurora Cannabis to Discuss Growth Strategy at TD Cowen Conference
- Conference Participation: Aurora Cannabis CFO Simona King will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026, where she is expected to engage in one-on-one meetings with investors, showcasing the company's leadership in the global medical cannabis market.
- Market Trends Discussion: The conference will explore significant shifts in the global medical cannabis landscape and their impact on industry growth, with Aurora sharing insights on its excellence in Canadian manufacturing, further solidifying its market position.
- Completion of Bevo Transaction: Aurora announced the completion of its transaction with Bevo Agtech Inc., initially announced on February 4, 2026, marking a significant step in expanding its product lines and market share.
- Global Expansion Strategy: As a global leader in medical cannabis, Aurora is committed to improving patient lives through scientific expertise and high-quality products, and will continue to expand its operations in markets such as Canada, Europe, and Australia.
See More
Aurora Cannabis to Discuss Growth Strategy at Health Care Conference
- Conference Participation: Aurora Cannabis will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026, where CFO Simona King will engage in discussions, likely drawing investor attention to its international leadership and market opportunities.
- Market Trends Discussion: The conference will address significant shifts in the global medical cannabis industry and market forces, with Aurora aiming to reinforce its market leadership by showcasing its excellence in Canadian manufacturing.
- Completion of Bevo Transaction: Aurora announced the completion of its transaction with Bevo Agtech Inc., previously disclosed on February 4, 2026, marking a strategic advancement in expanding its product lines and market share.
- Global Expansion Strategy: As a global leader in medical cannabis, Aurora is committed to improving patient lives through scientific expertise and high-quality products, and will continue to seek high-margin opportunities in Canada, Europe, and other markets.
See More
